Bingfeng Liu

Title: Innovations of Bingfeng Liu in HIV-1 Research

Introduction

Bingfeng Liu is a notable inventor based in Guangdong, China. He has made significant contributions to the field of biomedical research, particularly in the area of HIV-1 treatment. His innovative work focuses on developing novel therapeutic approaches to combat HIV-1 infections.

Latest Patents

Bingfeng Liu holds a patent for a VC-CAR molecule and its use in removing HIV-1 infected cells. This invention is characterized by linking an HIV-1 broad-spectrum neutralizing antibody VRC01 sourced scFv sequence with an intracellular domain sequence of a conventional CAR molecule. The VC-CAR molecule enables T cells modified with it to be specifically activated, leading to the secretion of a substantial amount of cytotoxicity-related cytokines. This mechanism allows for effective lysis of target cells, making it a promising candidate for anti-infection adoptive immunotherapy. He has 1 patent to his name.

Career Highlights

Bingfeng Liu is associated with Shenzhen City of Regeneration Biological Pharmaceutical Technology Co., Ltd. His work at this company emphasizes the application of his patented technology in real-world therapeutic settings. His research has the potential to significantly impact the treatment of HIV-1 infections.

Collaborations

Bingfeng Liu collaborates with talented individuals in his field, including Tao Wang and Fan Zou. Their combined expertise enhances the research and development efforts within their organization.

Conclusion

Bingfeng Liu's innovative contributions to HIV-1 research through his patented VC-CAR molecule demonstrate his commitment to advancing medical science. His work holds promise for improving treatment options for individuals affected by HIV-1.